Ampersand Health Revenue and Competitors

London, UK

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Ampersand Health's estimated annual revenue is currently $6.5M per year.(i)
  • Ampersand Health's estimated revenue per employee is $216,000

Employee Data

  • Ampersand Health has 30 Employees.(i)

Ampersand Health's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Product DirectorReveal Email/Phone
3
Content and Social Media LeadReveal Email/Phone
4
QA TesterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$36.8M231N/AN/AN/A
#2
$107.8M8989%$168M$694.4M
#3
$4.2M36N/AN/AN/A
#4
$225M407-12%$26.7M$2.7B
#5
$53740M5802371%N/A$223.5B
#6
$0.8M6N/AN/AN/A
#7
$18161M89463N/AN/AN/A
#8
$0.5M12N/AN/AN/A
#9
$4.9M44N/AN/AN/A
#10
$2.3M23N/AN/AN/A
#11
$4.4M39N/AN/AN/A
#12
$3.4M327%$70MN/A
#13
$0.4M6N/AN/AN/A
#14
$0.8M6N/AN/AN/A
#15
$5.4M48N/AN/AN/A
#16
$7.6M58N/AN/AN/A
#17
$11.8M84-18%$55.5MN/A
#18
$18.2M75N/AN/AN/A
#19
$25M10027%N/AN/A
#20
$13.3M95-16%$262.2MN/A
Add Company

What Is Ampersand Health?

keywords:N/A

N/A

Total Funding

30

Number of Employees

$6.5M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ampersand Health News

2022-04-20 - Permanency Specialist - Clinical Supports

Ampersand Families provides permanency and adoption services to older ... children's mental health and/or trauma-informed care preferred.

2022-04-19 - Calprotectin Testing Market to Surpass US$ 348.2 Mn by 2032 | Says FMI

In October 2021, Calpro AS & Ampersand Health collaborated to support self-management and remote monitoring of Inflammatory Bowel Disease (IBD).

2022-04-13 - Ampersand Health and UCB partner in new arthritis initiative

Ampersand Health and UCB have announced a partnership to help patients with Axial Spondyloarthritis (axSpA) – a form of inflammatory...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.3M30-27%$8M
#2
$3.5M30-14%N/A
#3
$4.1M30-21%N/A
#4
$3.5M30-6%$1M
#5
$7.8M307%N/A